| Literature DB >> 35845024 |
Niels Teich1, Chris Klecker1, Tobias Klugmann1, Peter Dietel1.
Abstract
Background and study aims The success of colonoscopy is mainly dependent on the effectiveness of prior bowel preparation (BP). Patients often consider BP to be the most burdensome part of colonoscopy, which might be a main barrier to the procedure. The aim of this study was to evaluate safety and effectiveness of colonic irrigation with a new colon hydrotherapy (CHT) device as an alternative to traditional oral BP. Patients and methods A prospective, non-randomized observational study was conducted to evaluate the quality of BP. A BP was considered effective if a score of 6 or better through the Boston Bowel Preparation Scale (BBPS) could be reached. Colonoscopy was performed immediately following colonic irrigation. For safety analysis, data on adverse events (AEs) were collected. Among the secondary outcomes, the BBPS assessed in each bowel segment and cecal intubation rate were analyzed. Results Twenty-eight consecutive patients (11 male [39.3%] and 17 [60.7 %] female) undergoing screening/surveillance or diagnostic colonoscopy were enrolled. Mean age was 54 ± 12.4 years (range 19-80). The evaluated mean BBPS was 7.8 ± 1.5. Twenty-five patients (89.3 %) had a BBPS score of 6 or above. Colonic irrigation was performed without any complications and no AEs were reported within 30 days. The cecal intubation rate was 100 %. Conclusions Colonic irrigation with a new CHT device is an effective and low-risk alternative to traditional oral preparation prior to colonoscopy. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).Entities:
Year: 2022 PMID: 35845024 PMCID: PMC9286771 DOI: 10.1055/a-1858-3728
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Demographics of the study population (N = 28).
|
|
|
|
| Gender | ||
Male | 11 (39.3 %) | |
Female | 17 (60.7 %) | |
| Age (years) | ||
Mean | 54 | |
SD | 12.4 | |
Min | 19 | |
Median | 55 | |
Max | 80 | |
| Patients had a previous colonoscopy with oral BP | N (%) | 08 (28.6 %) |
| Patients had a previous colonoscopy with CHT preparation | N (%) | 02 (7.1 %) |
| Patients had their first colonoscopy | N (%) | 18 (64.3 %) |
SD, standard deviation; BP, bowel preparation; CHT, colon hydrotherapy
Patients with risk factors for a poor preparation (N = 12).
|
|
|
| Diabetes mellitus | 1 (3.6 %) |
| IBD | 1 (3.6 %) |
| Hypothyroidism (full substituted) | 5 (17.9 %) |
| Obesity (defined as BMI ≥ 30 kg/m 2 ) | 2 (7.1 %) |
| Patient is taking one (or more) of the following drugs: tricyclic antidepressants, opioids or calcium antagonists | 3 (10.7) |
| Patients with risk factors for a poor preparation | 12 (42.9 %) |
IBD, inflammatory bowel disease; BMI, body mass index.
Distribution of total BBPS scores, mean and median BBPS.
|
|
|
| BBPS 9 | 11 (39.3 %) |
| BBPS 8 | 09 (32.1 %) |
| BBPS 7 | 03 (10.7 %) |
| BBPS 6 | 02 (7.1 %) |
| BBPS 5 | 01 (3.6 %) |
| BBPS 4 | 02 (7.1 %) |
| BBPS ≤ 3 | 00 (0) |
| Median BBPS | 08 |
| Mean BBPS | 07.8 |
| SD | 01.5 |
BBPS, Boston Bowel Preparation Score; SD, standard deviation.
Segmental Boston scores, RC, TC and LC (mean) and their distribution.
|
|
|
|
| BBPS 3: 20 (71.4 %) | ||
| LC | 2.7 ± 0.61 | BBPS 2: 7 (25.0 %) |
| BBPS 1: 1 (3.6 %) | ||
| BBPS 3: 21 (75.0 %) | ||
| TC | 2.7 ± 0.55 | BBPS 2: 5 (17.9 %) |
| BBPS 1: 2 (7.1 %) | ||
| BBPS 3: 14 (50.0 %) | ||
| RC | 2.4 ± 0.69 | BBPS 2: 11 (39.3 %) |
| BBPS 1: 3 (10.7 %) |
RC, right colon; TC, transverse colon; LC, left colon; BBPS, Boston Bowel Preparation Score.
BBPS ≥ 2 in colon segments.
|
|
|
|
|
|
|
|
|
|
| |||
| BBPS < 2 | 03 (10.7 %) | BBPS < 2 | 02 (7.1 %) | BBPS < 2 | 01 (3.6 %) |
|
|
|
| |||
| BBPS ≥ 2 | 25 (89.3 %) | BBPS ≥ 2 | 26 (92.9 %) | BBPS ≥ 2 | 27 (96.4 %) |
BBPS, Boston Bowel Preparation Score; RC, right colon; TC, transverse colon; LC, left colon.
Segmental and total BBPS scores in comparison to previous studies.
|
|
|
|
|
|
|
| ||||
| Own study data | 2.4 ± 0.69 | 2.7 ± 0.61 | 2.7 ± 0.55 | 7.8 ± 1.5 |
|
Godell 2021
| 2.5 ± 0.65 | 2.74 ± 0.52 | 2.81 ± 0.46 | 8.2 ± 1.38 |
|
Sportes 2017, CHT group
| 2.1 ± 0.6 |
2.6 ± 0.5
|
2.6 ± 0.5
| 7.3 ± 1.1 |
|
Gagneja 2016
| 2.47 | 2.71 | 2.78 | 7.96 |
|
| ||||
|
Bor 2020
| 2.67 ± 0.54 | 2.73 ± 0.46 | 2.79 ± 0.43 | 8.19 |
|
Haibin 2020
| 2.04 ± 0.84 | 2.25 ± 0.68 | 2.48 ± 0.64 | 6.77 ± 1.88 |
|
Bisschops 2018
| 2.2 (N2 D) | Data not available | Data not available | 6.7 ± 1.22 (N2 D) |
|
Sportes 2017, PEG group
| 2.4 ± 0.6 |
2.5 ± 0.5
|
2.5 ± 0.6
| 7.3 ± 1.2 |
|
Manes 2014
| 2.15 ± 0.75 (split-dose) | Data not available | Data not available | 7.25 ± 1.67 (split-dose) |
BBPS, Boston Bowel Preparation Score; RC, right colon; TC, transverse colon; LC, left colon; CHT, colon hydrotherapy; PEG, polyethylene glycol.
A retrospective analysis of patients who underwent colonoscopy (preparation with CHT; BBPS recorded for 7624 patients).
Assessed in transverse/ descending colon.
Assessed in sigmoid colon.
Observational study using oral preparation of MCSP.
A retrospective analysis of patients who underwent colonoscopy (preparation with PEG).
MORA study: assessing efficacy, safety and tolerability of oral products (NER1006 (Plenvu, 1 L PEG) N2 D (spit-dose) and N1 D (morning only) versus Moviprep, standard 2 L PEG in adult patients).
A multicenter, randomized, single-blind study using sodium picosulfate plus magnesium citrate (PMC) either in the standard or in split dosing.